We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Gvoke

News List

Xeris Pharmaceuticals Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke Kit for the Treatment of Severe Hypoglycemia drugs
August 25, 2021
Xeris today announced that its supplemental new drug application (sNDA) of Gvoke® Kit was approved by the Food and Drug Administration (FDA) for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes ages 2 years and above.
FDA grants regulatory approval for hypoglycemia treatment europeanpharmaceuticalreview
September 16, 2019
GVOKE injection has received regulatory approval from the FDA for the treatment of severe hypoglycemia in patients with diabetes.
FDA Approves Gvoke (glucagon), the First Ready-to-use Stable Liquid Glucagon for Severe Hypoglycemia drugs
September 12, 2019
Xeris Pharmaceuticals, Inc. a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations...
Xeris Pharmaceuticals Receives Notification of PDUFA Date Extension for Gvoke drugs
June 14, 2019
Xeris Pharmaceuticals Receives Notification of PDUFA Date Extension for Gvoke.